Xia Y - Search Results

1

Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy.

Xia Y, Du Z, Wang X, Li X. Xia Y, et al. Hum Gene Ther. 2018 Feb;29(2):242-250. doi: 10.1089/hum.2017.206. Hum Gene Ther. 2018. PMID: 29281902

2

Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment.

Xia Y, Wang L, Ma X, Li X. Xia Y, et al. Hum Gene Ther. 2020 Aug;31(15-16):881-890. doi: 10.1089/hum.2019.305. Epub 2020 Mar 27. Hum Gene Ther. 2020. PMID: 32013587

3

Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.

Qu H, Xia Y, Li X. Qu H, et al. Among authors: xia y. Curr Gene Ther. 2020;20(4):313-320. doi: 10.2174/1566523220666200826100245. Curr Gene Ther. 2020. PMID: 32851960

4

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.

Xia Y, Li X, Sun W. Xia Y, et al. Curr Gene Ther. 2020;20(2):127-141. doi: 10.2174/1566523220999200731003206. Curr Gene Ther. 2020. PMID: 32951572 Review.

5

Circ_0015756 promotes the progression of ovarian cancer by regulating miR-942-5p/CUL4B pathway.

Du Z, Wang L, Xia Y. Du Z, et al. Among authors: xia y. Cancer Cell Int. 2020 Nov 27;20(1):572. doi: 10.1186/s12935-020-01666-1. Cancer Cell Int. 2020. PMID: 33292255 Free PMC article.

6

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.

Du ZH, Xia Y, Yang Q, Gao S. Du ZH, et al. Among authors: xia y. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. Technol Cancer Res Treat. 2020. PMID: 33357097 Free PMC article.

7

From lab to clinic: The discovery and optimization journey of PI3K inhibitors.

Lian S, Du Z, Chen Q, Xia Y, Miao X, Yu W, Sun Q, Feng C. Lian S, et al. Among authors: xia y. Eur J Med Chem. 2024 Nov 5;277:116786. doi: 10.1016/j.ejmech.2024.116786. Epub 2024 Aug 20. Eur J Med Chem. 2024. PMID: 39180946 Review.

8

Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.

Xia Y, Wang H, Zhang J, Wang Y. Xia Y, et al. Int J Hyperthermia. 2023;40(1):2165729. doi: 10.1080/02656736.2023.2165729. Int J Hyperthermia. 2023. PMID: 36775583 Free article.

9

Synthetic routes and clinical application of new drugs approved by EMA during 2023.

Xia Y, Chen Q, Liu HN, Chi Y, Zhu Y, Shan LS, Dai B, Wu L, Shi X. Xia Y, et al. Eur J Med Chem. 2024 Nov 5;277:116762. doi: 10.1016/j.ejmech.2024.116762. Epub 2024 Aug 13. Eur J Med Chem. 2024. PMID: 39151275 Review.

10

Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase.

Chen Q, Xia Y, Liu HN, Chi Y, Li X, Shan LS, Dai B, Zhu Y, Wang YT, Miao X, Sun Q. Chen Q, et al. Among authors: xia y. Eur J Med Chem. 2024 Nov 5;277:116769. doi: 10.1016/j.ejmech.2024.116769. Epub 2024 Aug 13. Eur J Med Chem. 2024. PMID: 39163778 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,482 results

Search Page

Filters